Stereotaxis has announced a collaboration with Abbott to advance robotic electrophysiology. The partnership aims to integrate Abbott's EnSite X EP system, a 3D heart mapping system, with Stereotaxis' robotic magnetic navigation systems. By combining the cardiac mapping capabilities of Abbott's system with Stereotaxis' robotic technology, the collaboration seeks to enhance robotic surgery in the field of electrophysiology.
The collaboration between the two companies will enable real-time diagnostic information with the precision and stability offered by robotics during therapy delivery. The integration of their technologies is expected to improve the physician experience, streamline procedural workflow, and enhance the treatment of patients with abnormal heart rhythms.
Abbott's EnSite X system, which received FDA clearance in 2021, generates highly detailed three-dimensional maps of the heart, enabling physicians to identify and treat areas where abnormal rhythms originate. Stereotaxis' robotic magnetic navigation system utilises computer-controlled magnetic fields to provide direct control of a catheter tip in cardiac ablation procedures.
Stereotaxis and Abbott have successfully completed technology integration and conducted testing to demonstrate compatibility. The companies already have clearances for their technologies to be used in Europe, and they anticipate additional clearances in the coming months.
Dr. J. Peter Weiss, an electrophysiologist and clinical professor of medicine at Banner University of Arizona Medical Center, described the collaboration as a significant event in robotic electrophysiology. He believes that the joint use of these platforms will be beneficial for a wide range of cardiac ablation procedures.
Click here to read the original news story.